Message #9 From:
Stock News Bot Date: November 28, 2005 03:39:00 AM
CLSN News The Chelsea Collection Inc. Launches Program to Provide Exclusive G-H-3 Plus(R) Protocol Through Licensed Clinics
LAS VEGAS--(BUSINESS WIRE)--Nov. 28, 2005--G-H-3 International, a wholly owned subsidiary of The Chelsea Collection Inc. (Pink Sheets: CLSN), announced that the company has launched its program to provide the exclusive G-H-3 Plus(R) protocol in licensed medical clinics in the United States. The first licensed clinic to offer the G-H-3 Plus(R) protocol is Emerald Hills Medical Center in Hollywood, Fla., which will begin treating patients in December. Discussions with other potential licensees from Florida, California, Texas and other states will take place over the next three months.
"The company is very excited that we can now offer the G-H-3 Plus(R) protocol in America through licensed medical clinics," said Flo Ternes, president and CEO. "We anticipate licensing at least one new clinic in each quarter of 2006." The G-H-3 Plus(R) protocol will allow baby boomers and others who are concerned about the effects of aging and disease to utilize this proven and effective treatment without the expense and hassle of traveling to another country. Up until now, the G-H-3 Plus(R) protocol, developed by world-renowned geriatric doctor and researcher Dr. Ana Aslan, has only been available in European clinics, which have a waiting list.
This document contains "forward-looking statements" concerning CLSN/G-H-3 International Inc.'s operations and strategies, including its future economic performance, intent, plans, objectives, and the likelihood of success in developing and expanding the business. These statements are based upon assumptions and estimates that are subject to significant uncertainties, many of which are beyond G-H-3 International Inc.'s control. Words such as "may," "would," "could," "will," "expect," "anticipate," "intend," "plan," and "estimate," are meant to identify such forward-looking statements. Actual results may differ materially from those expressed or implied by such forward- looking statements. The company assumes no obligation to update this information.
